Stockscreener 앱 받기
5.81
4.91%
-0.30
전일 마감가:
$6.11
열려 있는:
$6.1
하루 거래량:
6.09M
Relative Volume:
1.07
시가총액:
$2.02B
수익:
$143.05M
순이익/손실:
$-145.99M
주가수익비율:
-13.57
EPS:
-0.4282
순현금흐름:
$-134.06M
1주 성능:
+1.93%
1개월 성능:
+26.86%
6개월 성능:
-27.74%
1년 성능:
+151.52%
1일 변동 폭
$5.81
$6.12
1주일 범위
$5.4801
$6.275
52주 변동 폭
$2.06
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
332-208-6102
주소
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.81 | 2.02B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-19 | 개시 | B. Riley Securities | Buy |
| 2025-09-30 | 개시 | Jefferies | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Does Nuvation Bio (NUVB) Have the Global Scale to Maximize Taletrectinib’s Regulatory Momentum? - Sahm
Nuvation Bio to offer $200M convertible senior notes - MSN
Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Nuvation Bio ups convertible notes offering to $287.5M after greenshoe exercise - MSN
NUVB Maintained by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
NUVB Maintained by Truist Securities -- Price Target Raised to $13.00 - GuruFocus
RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating - marketscreener.com
Nuvation Bio raises $287.5M in convertible notes offering - Investing.com UK
Nuvation Bio raises $287.5M in convertible notes offering By Investing.com - Investing.com South Africa
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering - PR Newswire
Price to earnings forward of Nuvation Bio Inc. – NYSE:NUVB - TradingView
Inventory turnover of Nuvation Bio, Inc. Class A – FWB:1E30 - TradingView
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
Nuvation Bio Inc. Bonds — Corporate Bond Rates - TradingView
Does Nuvation Bio’s (NUVB) U.K. Taletrectinib Milestone Hint at Durable Global Oncology Positioning? - Sahm
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative? - Yahoo Finance
Is Nuvation Bio (NYSE:NUVB) Building A Global Cancer Franchise? - Kalkine Media
Doctor-turned-dealmaker reveals his M&A playbook - Pharma Voice
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Nuvation Bio Announces $200 Million Convertible Senior Notes Offering to Repay Debt and Fund Growth Initiatives - Minichart
Nuvation Bio Prices $250 Million 0.75% Convertible Notes Due 2032, Repays $58.5 Million Loan - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
MHRA validates Nuvation Bio’s taletrectinib application in UK - Investing.com UK
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell 2000 Value Benchmark - marketscreener.com
Nuvation Bio's Taletrectinib Enters UK Regulatory Review - Moomoo
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
MHRA validates Nuvation Bio’s taletrectinib application in UK By Investing.com - Investing.com Nigeria
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - PR Newswire
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell 3000E Value Benchmark - marketscreener.com
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Nuvation Bio prices $250M convertible notes offering - MSN
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes - Rockdale Citizen
Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB) - TradingView
Nuvation Bio prices $250M convertible notes offering By Investing.com - Investing.com Canada
Nuvation Bio Announces Proposed Convertible Senior Notes Offering - Investing News Network
NUVB Stock Builds Momentum As Charts And Cash Position Strengthen - StocksToTrade
Why is Nuvation Bio stock sliding today? - Investing.com
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):